Aptar Digital Health has partnered with Guy’s and St Thomas’ NHS Foundation Trust in the UK to evaluate the impact of its digital Respiratory Disease Management Platform (ADH Respiratory DMP) on asthma patients in a study.
Commenced in July 2024, the study will involve 118 adult subjects with moderate to severe asthma and will last for 12 months.
Go deeper with GlobalData
The clinical study aims to assess the improvement of asthma symptom control among participants.
The two organisations are collaborating with the Clinical Research Organization (CRO) Lindus Health to execute the study.
Clinical data will be evaluated such as quality of life, asthma control symptoms, medication adherence, healthcare resource utilisation, and satisfaction with the digital solution.
The ADH Respiratory DMP will help enhance asthma symptom control, technique, and patient engagement.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt includes a mobile application for patients that connects to inhaler sensors such as the HeroTracker Sense, and a software portal intended for healthcare professionals.
The platform offers reminders, real-time tracking, and educational resources to manage medication and symptoms.
Aptar Digital Health chief medical officer Geneviève d’Orsay said: “Our respiratory platform previously demonstrated potential to improve asthma control and decrease rescue medication use in the US, and we are excited to study our enhanced platform as part of this clinical study.”
Guy’s and St Thomas’ NHS Foundation Trust asthma and eosinophilic lung diseases consultant David Jackson is the chief investigator of the clinical study.
Jackson said: “Poor adherence to inhaled steroids remains the biggest barrier to asthma control. At the same time, a failure to identify and correct suboptimal adherence leads to unnecessary escalation to very costly biologic agents due to the incorrect assumption many patients have severe asthma when they do not.
“As such, electronic monitoring of ICS adherence has enormous potential to both improve quality of care and reduce healthcare costs in asthma, and we are excited to start this study with the aim of demonstrating this.”
In June 2024, Aptar Digital collaborated with SHL Medical to enhance the patient experience in injectable therapies by integrating digital health solutions with advanced drug delivery systems.
